Pulmonary expanded polytetrafluoroethylene conduits with a hand-sewn tricuspid valve.

Abstract

Objectives: The biocompatibility of expanded polytetrafluoroethylene in the pulmonary position seems better than allogenic or xenogeneic reactivity. This study reviewed the application of pulmonary expanded polytetrafluoroethylene conduits having a hand-sewn tricuspid valve with diameters of 18-24 mm.

Methods: All patients receiving this conduit between 2010 and 2022 were evaluated. A 0.1-mm thick membrane and a standard-wall tube of expanded polytetrafluoroethylene were used for cusp and conduit material, respectively.

Results: Eighty-four consecutive patients were included. The median operative age and weight were 12 (range, 1.2-40) years and 34 (range, 9.1-82) kg, respectively. Eighteen-, 20-, 22-, and 24-mm conduits were used in 19, 5, 3, and 57 patients, respectively. The overall survival was 94% at 5 and 10 years with 4 non-valve-related deaths. There were 5 conduit replacements, all for 18-mm conduit stenosis. Freedom from conduit replacement was 98% and 83% at 5 and 10 years, respectively. Freedom from conduit stenosis ≥ moderate was 83% and 54% at 5 and 10 years, respectively. Freedom from pulmonary regurgitation ≥ moderate was 98% at 5 and 10 years. Linear mixed-effects models with echocardiographic data implied that 24-mm conduits functioned with a peak velocity < 3.0 m/second and without moderate/severe regurgitation in patients with a body weight of up to 75 kg and a body surface area of up to 2.0 m2 for > 12 years postoperatively.

Conclusions: This conduit has shown favourable clinical outcomes and is a valid alternative, especially in young patients with increased risk for early failure of the existing products.